JCR Pharmaceuticals Co., Ltd.
Q1 FY2027 Financial Results Conference
JCR Pharma achieved net sales of 9,700 million yen in the first quarter of FY2027, a 13.2% increase YoY, with gross profit reaching 7,450 million yen, a 19.9% YoY increase. Research and development expenses and selling expenses also increased, leading to an operating income of 2,103 million yen, significantly expanding profitability.
Key Figures
- Net Sales: 9,700 million yen (YoY +13.2%)
- Gross Profit: 7,450 million yen (YoY +19.9%)
- Operating Income: 2,103 million yen (YoY +85.4%)
AI要約
Performance Overview
In the first quarter of FY2027, JCR Pharma recorded net sales of 9,700 million yen (up 13.2% YoY), and gross profit of 7,450 million yen (up 19.9% YoY). Although research and development expenses and selling expenses increased, operating income expanded significantly to 2,103 million yen, showing improved profitability. The growth is driven by expanded pharmaceutical sales and proactive research investments.
Future Outlook and Investor Impact
The company plans to continue strengthening its research, development, and sales activities to expand sales and profits. Approval of new drugs and progress in overseas expansion are expected to support long-term growth. For investors, increased profitability and active research investment are viewed as value-enhancing strategies for the company.
Net Sales Trend
Operating Income Trend
JCR Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
